此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Comparison of Two Probiotics for Reducing Diarrhea Frequency in Children Aged 6-24 Months

2026年11月2日 更新者:King Edward Medical University

Comparison of the Effectiveness of Saccharomyces Boulardii CNCM I-745 and Multi-Strain Bacillus Clausii in Reducing the Frequency of Acute Watery Diarrhea in Children Aged 6 to 24 Months

Clinical Trial Summary

The goal of this clinical trial is to compare the effectiveness of Saccharomyces boulardii CNCM I-745 and multi-strain Bacillus clausii in reducing the frequency of acute watery diarrhea in children aged 6 to 24 months. The main question it aims to answer is:

- Which probiotic is more effective in reducing the daily frequency of acute watery diarrhea in children?

Researchers will compare Saccharomyces boulardii CNCM I-745 with a four-strain mixture of Bacillus clausii (O/C, SIN, N/R, T) to determine which is more effective in reducing diarrhea frequency.

Participants will:

  • Receive either Saccharomyces boulardii CNCM I-745 at a daily dose of 10 billion CFU or multi-strain Bacillus clausii at a daily dose of 4 billion CFU for 3 days.
  • Receive standard treatment for diarrhea, including oral rehydration therapy (ORS), zinc supplementation, and dietary advice.
  • Be followed for 3 days after admission, with daily recording of the frequency of diarrhea episodes.

研究概览

详细说明

- Background and Rationale

Acute watery diarrhea is an important cause of morbidity among children under five years of age, particularly in resource-limited settings. In young children, ongoing fluid loss can result in dehydration and may lead to serious complications if appropriate management is delayed. The mainstay of treatment is oral rehydration therapy (ORS), zinc supplementation, continued breastfeeding, and appropriate dietary management. Probiotics have also been used as adjuncts to standard treatment, with the aim of improving clinical recovery. However, the effectiveness of probiotics may vary according to the specific microorganism and strain used.

Saccharomyces boulardii CNCM I-745 is a yeast probiotic that has been investigated for its role in pediatric acute gastroenteritis. Bacillus clausii is a spore-forming bacterial probiotic, and the four strains O/C, SIN, N/R, and T have also been used in the management of gastrointestinal disorders, including diarrhea in children. Although both preparations have been studied individually, direct comparisons between these probiotic preparations in children with acute watery diarrhea remain limited.

Differences in their biological characteristics and the limited availability of direct comparative evidence provide a rationale for evaluating these two preparations within the same clinical setting and study population. Such a comparison may contribute to a better understanding of their relative effectiveness when used alongside standard treatment.

- Study Purpose

The purpose of this study is to compare the effectiveness of *Saccharomyces boulardii* CNCM I-745 and a four-strain preparation of *Bacillus clausii* (O/C, SIN, N/R, and T) in reducing the daily frequency of acute watery diarrhea in young children.

The study focuses on the change in the frequency of diarrhea episodes during the treatment and observation period. The comparison is intended to determine whether the two probiotic preparations differ in their effectiveness when administered with standard management for acute watery diarrhea.

- Study Design and Conduct

This is a randomized, open-label clinical trial conducted in the Children Emergency and Outpatient Department of Paediatric Medicine Unit-II, King Edward Medical University / Mayo Hospital, Lahore, Pakistan.

The study plans to include 88 children, with 44 participants allocated to each treatment group. Participants will be selected using non-probability convenient sampling from children presenting to the study setting who meet the protocol-defined selection criteria. After assessment for eligibility and obtaining written informed consent from a parent or guardian, participants will be allocated to one of the two groups using a lottery method.

The study is open-label, meaning that treatment allocation is not blinded to the participants' caregivers or the study team. Both groups will receive the same general standard management for diarrhea, including oral rehydration therapy, zinc supplementation, and dietary advice. This approach allows the daily frequency of diarrhea to be compared between the two probiotic treatment groups under the same clinical setting and observation period.

- Clinical Assessment and Data Collection

At enrollment, a clinical assessment will be performed, and relevant demographic and clinical information will be recorded on the study proforma. This includes age, sex, weight, vital signs, the onset of diarrhea, and the reported frequency of diarrhea during the preceding 24 hours. Clinical assessment will also establish whether the child meets the protocol's definition of acute watery diarrhea with some dehydration.

During the study period, the frequency of diarrhea episodes will be documented daily. Participants will be followed for three days after admission, and the recorded information will be used to compare the two groups. The study will assess the daily stool frequency observed during follow-up rather than assume that one probiotic is more effective than the other.

- Data Analysis and Interpretation

Study data will be entered and analyzed using Statistical Package for the Social Sciences (SPSS), version 26. Quantitative variables, including age, weight, and stool frequency, will be summarized using means and standard deviations. The independent-samples t-test will be used for comparisons of quantitative variables as specified in the study protocol. Qualitative variables, including sex, dehydration status, and nutritional status, will be summarized as frequencies and percentages and compared using the chi-square test. A p-value of less than 0.05 will be considered statistically significant.

The findings will be interpreted by comparing the recorded diarrhea frequency between the two treatment groups. The results may help inform clinical decision-making regarding the choice of probiotic as an adjunct to standard treatment in children with acute watery diarrhea. The study is intended to provide evidence from a local pediatric clinical setting; its findings will be interpreted in the context of its sample size, study design, and follow-up period.

研究类型

介入性

注册 (估计的)

88

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Dr. Aniqua Tahir Tahir, MBBS, MD Paediatrics
  • 电话号码:03454078234
  • 邮箱:aniqua_tahir@yahoo.com

研究联系人备份

  • 姓名:Dr. Mimpal Singh Associate Professor, Paediatrics, MBBS, MCPS, MD, DCH, PHD, PGPN
  • 电话号码:03334229251
  • 邮箱:singh.ms1437@gmail.com

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

6个月 至 2年 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria

  • Children aged 6 to 24 months.
  • Children of either sex.
  • Children with a clinical diagnosis of acute watery diarrhea, defined as three or more loose/liquid stools per day for less than 14 days, with some dehydration.
  • Children able to take oral medication.

Exclusion Criteria

  • Children with severe systemic illness, including immunodeficiency, sepsis, or congenital gastrointestinal anomalies.
  • Children with severe malnutrition.
  • Children who received systemic antibiotics, probiotics, or medications affecting gastrointestinal motility, including laxatives, antiemetics, antisecretory agents, adsorbent medications, or opiates, within 7 days before enrollment.
  • Children with a known allergy or hypersensitivity to either study probiotic or any of its formulation components.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Saccharomyces boulardii CNCM I-745

Participants assigned to this arm will receive Saccharomyces boulardii CNCM I-745 at a daily dose of 10 billion CFU (1 × 10¹⁰ CFU/day) for 3 days. Standard management, including oral rehydration solution (ORS), zinc supplementation, and dietary advice, will also be provided.

Probiotic yeast preparation containing Saccharomyces boulardii CNCM I-745, administered orally at a daily dose of 10 billion colony-forming units (CFU) for 3 days.

其他名称:
  • 恩福尔
实验性的:Multi-strain Bacillus clausii (O/C, SIN, N/R, and T)

Participants assigned to this arm will receive multi-strain Bacillus clausii (O/C, SIN, N/R, and T) at a daily dose of 4 billion CFU (4 × 10⁹ CFU/day) for 3 days. Standard management, including oral rehydration solution (ORS), zinc supplementation, and dietary advice, will also be provided.

Four-strain probiotic preparation containing Bacillus clausii strains O/C, SIN, N/R, and T, administered orally at a daily dose of 4 billion colony-forming units (CFU) for 3 days.

其他名称:
  • 肠胚门

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Daily frequency of diarrhea episodes
大体时间:Day 1 through Day 3 after admission (3 days)

Number of diarrhea episodes per day, recorded daily for 3 days after admission in children aged 6-24 months receiving either Saccharomyces boulardii CNCM I-745 or multi-strain Bacillus clausii, alongside standard treatment for diarrhea.

Day 1 through Day 3 after admission (3 days)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Dr. Aniqua Tahir, MBBS, MD Paediatrics、King Edward Medical University / Mayo Hospital Lahore

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2027年2月1日

研究完成 (估计的)

2027年2月1日

研究注册日期

首次提交

2026年10月29日

首先提交符合 QC 标准的

2026年11月2日

首次发布 (实际的)

2026年11月6日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared with other researchers because the study involves young children and the research team intends to protect participant confidentiality and privacy. The data will be used for the purposes of the planned research and reporting of study results in aggregate form.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅